标题：乳腺癌术后放疗联合复方苦参注射液治疗对患者免疫功能及生存质量的影响

      作者：司马义力·买买提尼牙孜，艾秀清，朱相露，王义海，木妮热·木沙江
    (新疆医科大学附属肿瘤医院乳腺放疗科，新疆 乌鲁木齐 830011)

      卷次： 2016年27卷14期

      【摘要】 目的 观察术后放疗联合复方苦参注射液治疗乳腺癌的临床疗效及其对患者细胞免疫功能及生活
质量的影响，为临床乳腺癌患者术后治疗提供有力依据。方法 回顾性分析我院乳腺放疗科 2013年 1月至
2014年 12月收治的 128例术后放疗乳腺癌患者的临床诊治资料，其中术后放疗者 64例为对照组，术后放疗联合
复方苦参注射液静脉滴注者 64例为观察组，共治疗 6个月。于治疗前及治疗 6个月后第二天检测两组患者的细
胞免疫功能，比较两组患者美容效果、生活质量和不良反应。结果 治疗 6个月后观察组患者的CD3+、CD4+、
NK细胞及 CD4+/CD8+值较治疗前明显提高[(65.7±6.9) vs (58.3±8.1)、(38.7±4.9±6.9) vs (24.5±3.0)、(65.6±8.3)% vs
(39.6±5.3)%、(1.18±0.21) vs (0.59±0.14)]，而CD8+值较治疗前明显下降[(31.0±2.9) vs (42.7±4.5)]，差异均有统计学意
义(P<0.05)；对照组患者的CD8+及NK细胞数较治疗前稍增加[(43.3±4.4) vs (42.1±4.9)、[(41.3±5.8)% vs (40.1±5.1)%]，
其他指标较治疗前略下降，差异均无统计学意义(P>0.05)；观察组患者的美容优良率为92.2% (59/64)，略优于对照
组 89.1% (57/64)，差异无统计学意义(P>0.05)；观察组患者的生存质量改善者 52例(81.3%)，明显高于对照组 30例
(46.9%)，差异有统计学意义(P<0.05)；观察组患者的皮肤反应和骨髓抑制明显优于对照组，差异均有统计学意义
(P<0.01)。结论 术后应用复方苦参注射液联合放疗治疗乳腺癌，其可减少不良反应，增强患者细胞免疫功能，且
术后不会对乳房美容效果产生较大影响，有利于改善患者生活质量。

      【关键词】 复方苦参注射液；放疗；乳腺癌；细胞免疫功能；生活质量

      【中图分类号】 R737.9 【文献标识码】 A 【文章编号】 1003—6350（2016）14—2283—03


Effects of breast cancer postoperative radiotherapy combined with compound matrine injection on its immune
function and quality of life.
Simayili·Maimaitiniyazi, AI Xiu-qing, ZHU Xiang-lu, WANG Yi-hai, Munire·Mushajiang.
Department of Radiotherapy, the Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, Xinjiang, CHINA

【Abstract】 Objective To observe the clinical efficacy of postoperative radiotherapy combined with compound
matrine injection in the treatment of breast cancer and its effect on the cellular immune function and quality of life, and
to provide a strong basis for the clinical treatment of patients with breast cancer. Methods The clinical data of 128 pa-
tients with breast cancer undergoing postoperative radiotherapy in Department of Radiotherapy in our hospital from De-
cember 2014 to January 2013 were retrospectively reviewed, of which the 64 patients were treated with postoperative ra-
diotherapy as the control group, while the other 64 patients were treated with radiotherapy combined with compound ma-
trine injection as the observation group, with treatment for 6 months. Before treatment and 6 months after treatment, the
cellular immune function of the two groups were detected on the second day after treatment. The cosmetic effect, quality
of life and adverse reactions were compared between the two groups. Results Compared with before treatment, the val-
ues of CD3 + , CD4 + , NK cells and CD4 +/CD8 + after 6 months of treatment were significantly increased [(65.7±6.9) vs
(58.3±8.1), (38.7±4.9±6.9) vs (24.5±3.0), (65.6±8.3)% vs (39.6±5.3)%, (1.18±0.21) vs (0.59±0.14)], and the values of
CD8 + were significantly decreased [(31.0±2.9) vs (42.7±4.5)], with statistically significant differences (P<0.05). Com-
pared with before treatment, the number of CD8 + and NK cells in control group was slightly increased [(43.3±4.4) vs
(42.1±4.9), [(41.3±5.8)% vs (40.1±5.1)%], and other indicators were slightly decreased, with no statistically significant
difference (P>0.05). The excellent cosmetic rate in the observation group was slightly better than the control group
[92.2% (59/64) vs 89.1% (57/64)], with no statistically significant difference (P>0.05). The quality of life improvement
in the observation group was significantly higher than that in the control group [52 (81.3%) vs 30 (46.9%)], and the dif-
ference was statistically significant (P<0.05). The skin reaction and bone marrow inhibition of the observation group
were significantly better than those of the control group, and the differences were statistically significant (P<0.01).
Conclusion Postoperative application of compound matrine injection combined with radiotherapy for breast cancer,
can reduce adverse reaction, enhance the cellular immune function in patients, and it will not have a greater impact on
the breast cosmetic effect, which is helpful to improve patients' quality of life.

      【Key words】 Com